Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K
Ethics in Research01:56

Ethics in Research

22.9K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
22.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Blind Procedures02:07

Blind Procedures

10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A national survey of clinical informatics educational opportunities in United States medical schools.

Journal of the American Medical Informatics Association : JAMIA·2026
Same author

Symptom-based rehabilitation in people with post-COVID-19 condition (RELOAD study): a randomised controlled trial.

BMJ open respiratory research·2026
Same author

Large Language Model Performance and Clinical Reasoning Tasks.

JAMA network open·2026
Same author

Small intestinal microbial fiber metabolism dysfunction in celiac disease.

Nature communications·2026
Same author

RapidParc: A global-context transformer for parallel, accurate, and lesion-robust tractogram parcellation.

Imaging neuroscience (Cambridge, Mass.)·2026
Same author

Cardiac risk, outcomes, and management among older adults with stage I-II non-small cell lung cancer undergoing stereotactic body radiation therapy.

Journal of geriatric oncology·2026

相关实验视频

Updated: Jun 16, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.1K

关于直接面向消费者的测试监管的公众观点

Sharon Jiang1,2, David Lebo3, Thomas Schultz3

  • 1School of Pharmacy, Temple University, Philadelphia, PA, USA. sharon.jiang@temple.edu.

Therapeutic innovation & regulatory science
|August 17, 2024
PubMed
概括

美国食品和药物管理局最终确定了一项实验室开发测试 (LDT) 的规则,逐步取消了大多数LDT的执法自由裁量权,但豁免了直接向消费者 (DTC) 的测试. 公众的评论凸显了人们的担忧,特别是在DTC测试方面.

关键词:
关于DTC规定的规定DTC测试试验测试试验 DTC测试试验直接向消费者提供服务.美国食品和药物管理局执法裁量权.美国食品和药物管理局 (FDA) 提出关于LDT的规则.

更多相关视频

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

9.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

相关实验视频

Last Updated: Jun 16, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.1K
Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

9.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

科学领域:

  • 医疗器械规则 医疗器械规则
  • 临床诊断 临床诊断 临床诊断
  • 公共卫生政策 公共卫生政策

背景情况:

  • 美国食品和药物管理局 (FDA) 在2024年5月6日发布了一项关于医疗器械的最终规则;实验室开发的测试 (LDTs).
  • 该规则修改了法规,以确保LDT的安全性和有效性.
  • 它标志着远离FDA之前对LDT的一般执法自由裁量权政策的转变,将它们与体外诊断器件保持一致.

研究的目的:

  • 分析公众对拟议的FDA关于LDT规则的反应和担忧.
  • 在新的监管框架内,专门研究与直接向消费者 (DTC) 测试相关的问题.
  • 为改善LDT,特别是DTC测试的监管和监督提供建议.

主要方法:

  • 在制定规则过程中提交的公众意见的分析 (建议于2023年10月3日).
  • 专注于有关DTC测试和混合DTC模型的评论.
  • 审查现有的FDA政策和诊断测试的监管方法.

主要成果:

  • 最终规则将DTC测试排除在政策转变之外,并引用现有的适用要求.
  • 大量的公众评论揭示了关于LDT规则的关键问题和建议.
  • 评论强调需要重新评估混合DTC测试的执法自由裁量权,并澄清临床监督.

结论:

  • 建议包括重新评估FDA对混合DTC测试的执法裁量权.
  • 倡导对LDT临床监督的明确监管指导至关重要.
  • 优先考虑基于风险的执法方法,加强对DTC测试风险的公众教育,对于保护公共健康至关重要.